BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

NIH funding for AIDS research

12 June 2017 | News

Experts in implementation science will determine and apply the most effective ways to provide patient care, therapies, testing, and pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) medications to prevent HIV acquisition.



The National Institutes of Health has awarded researchers at Albert Einstein College of Medicine, The Rockefeller University, The City University of New York Graduate School of Public Health and Health Policy (CUNY), a $7.5 million grant for the Center for AIDS Research focused on preventing HIV transmission and ending the AIDS epidemic.

The Einstein-Rockefeller-CUNY Center for AIDS Research (ERC-CFAR) is driving a "bench-to-bedside-to-community and back-to-the-bench" research agenda, with resources devoted to behavioral science, clinical translation of research findings into novel treatments, the discovery of biomarkers, applying advanced technologies for improving clinical outcomes and developing an HIV vaccine. Experts in implementation science will determine and apply the most effective ways to provide patient care, therapies, testing, and pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) medications to prevent HIV acquisition.

A major focus of the ERC-CFAR's mission is to translate research into sustainable implementation of population level interventions and strategies that have the potential to improve HIV-related outcomes and reduce health disparities on a large scale.

The leadership team of the center includes two additional associate directors- Sarah Schlesinger, M.D., of Rockefeller, who is an expert on designing and implementing immune-based clinical trials to prevent HIV-1 infection and Betsy Herold, M.D., of Einstein, who is a leader in developing safe and effective topical microbicides for preventing HIV, genital herpes and other sexually transmitted infections.